Sporotrichosis
Online Inquiry

Sporotrichosis

Sporotrichosis, which is caused by the dimorphic fungus Sporothrix schenckii, is a fungal infection caused by the pathogen sporothrix species. For such unusual diseases as sporotrichosis our company provides focused, high-quality services for the researchers and scientists working in the unique field.

Overview of Sporotrichosis

Sporotrichosis is primarily cutaneous mycosis that affects the skin, subcutaneous, and lymphatic system. Its most common form of transmission is through an accident or injury that exposes the skin to fungus mostly from infected soil or vegetation. Besides, being scratched or bitten by infected animals is another common way of getting the infection. There exist two main types of sporotrichosis: cutaneous and extracutaneous sporotrichosis.

Agents of human and animal sporotrichosis.Fig.1 Phylogenetic analysis of the main members of medical relevance in the genus Sporothrix. (Rodrigues, A. M., et al., 2022)

Pathogenesis of Sporotrichosis

Sporotrichosis is an infective disease that is caused primarily by the dimorphic fungus Sporothrix schenckii and its related species, which can be found in vegetation, decaying organic materials, Sphagnum moss, and soil around the world. This fungus penetrates the body through open skin, usually creating a small, soft bump that is not painful at the site of entry. The infection progresses along the lymphatic channels and may lead to a series of nodules or ulcers. In some cases, especially in those who are immunocompromised, the infection can spread to bones and joints and also the lungs.

Drug targets of sporotrichosis.Fig.2 The main antifungal agents and their cellular targets. (Rodrigues, A. M., et al., 2022)

Vaccine and Therapeutic Development for Sporotrichosis

Types Names Mechanism of Action Targets Research Phase
Vaccine development MAb P6E7 A monoclonal antibody against cell wall Gp70 glycoprotein Gp70 glycoprotein Preclinical research
ZR8 peptide Induce the cellular immune response GP60-70 protein Preclinical research
PGA+CWP100 Increase anti-ssCWP IgG, IgG1, IgG2a, and IgG3 levels ssCWP Preclinical research
Therapeutic development Potassium iodide Inhibit biofilm development in Sporothrix / Approved
Itraconazole Inhibit the synthesis of ergosterol CYP51A1 Approved
Terbinafine Inhibitor of ergosterol synthesis SQLE Approved
TCAN26 Cell membrane disruption / Preclinical research
Buparvaquone Mitochondrial dysfunction / Preclinical research
Miltefosine Cell membrane disruption CCT Approved

Our Services

Our company specializes in infectious disease therapy development and has built great proficiencies in infectious disease modeling, vaccine and therapeutic development, and seamless service. We ensure that researchers looking for services or laboratory facilities have all the necessary tools to further their studies on sporotrichosis.

Featured Services for Sporotrichosis

Our services bring a focus on accurate synergy with a plethora of resources and skillful expertise so that scientists and researchers can work towards eradicating diseases like sporotrichosis. To find out more about how to get in touch with our services, or for any other information or quotations related to our work, please do not hesitate to reach out to us.

References

  1. Rodrigues, Anderson Messias et al. "Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends." Journal of fungi (Basel, Switzerland) 8.8 (2022): 776.
  2. Sharma, Bunty et al. "Sporotrichosis: a Comprehensive Review on Recent Drug-Based Therapeutics and Management." Current dermatology reports 11.2 (2022): 110-119.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

x